249 related articles for article (PubMed ID: 22896685)
41. Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer.
Li S; Cao J; Zhang W; Zhang F; Ni G; Luo Q; Wang M; Tao X; Xia H
Sci Rep; 2016 Nov; 6():36873. PubMed ID: 27833130
[TBL] [Abstract][Full Text] [Related]
42. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
43. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract][Full Text] [Related]
44. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
45. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.
Castellarin M; Milne K; Zeng T; Tse K; Mayo M; Zhao Y; Webb JR; Watson PH; Nelson BH; Holt RA
J Pathol; 2013 Mar; 229(4):515-24. PubMed ID: 22996961
[TBL] [Abstract][Full Text] [Related]
46. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
47. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
Kim O; Park EY; Klinkebiel DL; Pack SD; Shin YH; Abdullaev Z; Emerson RE; Coffey DM; Kwon SY; Creighton CJ; Kwon S; Chang EC; Chiang T; Yatsenko AN; Chien J; Cheon DJ; Yang-Hartwich Y; Nakshatri H; Nephew KP; Behringer RR; Fernández FM; Cho CH; Vanderhyden B; Drapkin R; Bast RC; Miller KD; Karpf AR; Kim J
PLoS Genet; 2020 Jun; 16(6):e1008808. PubMed ID: 32497036
[TBL] [Abstract][Full Text] [Related]
48. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
49. Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.
Tuna M; Ju Z; Smid M; Amos CI; Mills GB
Mol Cancer; 2015 Feb; 14(1):29. PubMed ID: 25644622
[TBL] [Abstract][Full Text] [Related]
50. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
51. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
52. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
53. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
[TBL] [Abstract][Full Text] [Related]
54. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
55. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
56. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
57. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
[TBL] [Abstract][Full Text] [Related]
58. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
59. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract][Full Text] [Related]
60. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]